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Abstract
Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by loss of normal atonia during REM sleep, such that patients appear to act out
their dreams. The most important implication of research into this area is that patients with idiopathic RBD are at very high risk of developing synuclein-
mediated neurodegenerative disease (Parkinson’s disease [PD], dementia with Lewy bodies [DLB], and multiple system atrophy), with risk estimates that
approximate 40–65% at 10 years. Thus, RBD disorder is a very strong feature of prodromal synucleinopathy. This provides several opportunities for future
research. First, patients with REM sleep behavior disorder can be studied to test other predictors of disease, which could potentially be applied to the general
population. These studies have demonstrated that olfactory loss, decreased color vision, slowing on quantitative motor testing, and abnormal substantia nigra
neuroimaging findings can predict clinical synucleinopathy. Second, prospectively studying patients with RBD allows a completely unprecedented opportunity
to directly evaluate patients as they transition into clinical neurodegenerative disease. Studies assessing progression of markers of neurodegeneration in
prodromal PD are beginning to appear. Third, RBD are very promising subjects for neuroprotective therapy trials because they have a high risk of disease
conversion with a sufficiently long latency, which provides an opportunity for early intervention. As RBD research expands, collaboration between centers will
become increasingly essential.
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Introduction
Rapid eye movement (REM) sleep behavior disorder (RBD) is
characterized by dysfunction of systems that produce the normal REM
atonia of sleep, such that patients appear to act out the content of their
dreams.1 Generally, diagnosis requires a polysomnogram to confirm the
loss of REM sleep atonia and to rule out potential confounders, such as
apnea. Symptomatic treatment, with clonazepam or melatonin, is usually
successful.
Of special interest is the connection between RBD and neurodegen-
eration. Although it has been associated with diverse neurodegenerative
disorders, RBD is most prominently caused by synucleinopathies –
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple
system atrophy.
Studying RBD within established clinical synucleinopathies has
provided numerous important insights; for example, RBD may be a
marker of a certain PD subtype, as well as a risk factor for dementia in
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PD.2,3 In the case of established dementia, RBD can be useful as a
strong diagnostic marker for DLB as the underlying pathology.4,5
However, the most important implication of this research is that RBD
can anticipate the full development of synucleinopathies; that is, RBD
is a prodromal marker of PD. This has been confirmed in four sleep
center cohort studies and one population-based study – in these
studies, risks for development of neurodegeneration were approxi-
mately 25–40% at 5 years and 40–65% at 10 years.6–10 Approximately
half of RBD patients develop parkinsonism (most commonly PD), and
half develop dementia. However, studies suggest considerable overlap
between conditions, with most patients demonstrating both cognitive
impairment and parkinsonism in the first years after diagnosis.11 Such
a high risk of disease provides an unprecedented opportunity to
directly observe prodromal stages of neurodegenerative disease.
The potential for the future of RBD research is vast; however, three
aspects of the relationship between RBD and prodromal PD are of
particular promise. First, the potential to test disease predictors;
second, the ability to directly observe the evolution of prodromal PD;
and third, the potential to develop neuroprotective therapies.
Testing disease predictors
Neurodegenerative diseases such as PD almost always begin
gradually and have a long prodromal interval, during which time
RBD can be a prominent feature. However, idiopathic RBD patients
rarely present to clinics for evaluation. This limits our ability to use
idiopathic RBD as a marker for prodromal neurodegeneration in the
general population. This may eventually change – several screening
tools to assess RBD in the general population have been developed,
some of which have reported sensitivity and specificities greater than
80%.12–14 Moreover, even before large-scale assessment of idiopathic
RBD is performed, known RBD patients can be studied to test other
prodromal neurodegenerative markers. By investigating RBD, pre-
dictive/diagnostic markers can be directly tested before diagnosis of
neurodegenerative disease.
Several studies have assessed potential markers of neurodegenera-
tion in patients with RBD. They have demonstrated that patients with
idiopathic RBD have a higher prevalence of autonomic dysfunction,15–17
depression,15 subtle motor problems,15,18 mild cognitive changes,19
olfactory loss,20,21 and color vision loss.21 In addition, there are
numerous abnormalities in potential ancillary markers, including
dopaminergic functional neuroimaging,20,22 transcranial substantia
nigra ultrasound,22 electroencephalogram spectral analysis,23 whole-
brain glucose utilization,24,25 diffusion-weighted magnetic resonance
imaging (MRI),26,27 and MRI volumetry.26 All of these features have also
been found early in the course of neurodegenerative synucleinopathies;
their documentation in RBD suggests that they may be present before
full motor PD or DLB develops.
There is now direct evidence from prospective studies that at least
some of these markers can identify prodromal PD. In prospective
studies assessing olfaction in idiopathic RBD, those with abnormal
olfaction at baseline had a 65% risk of developing neurodegenerative
disease, compared to a 14% risk in those with normal olfaction,21
Similarly, those with abnormal color vision had a 74% risk of
neurodegenerative synucleinopathy compared to 26% in those with
normal test results21 (subsequent studies have suggested that color
vision correlates closely with posterior visuoperceptual dysfunction,
and may therefore be a more useful marker of DLB [Bertrand et al, in
press]). Prospective studies assessing dopaminergic single-photon
emission computed tomography (SPECT) imaging found that 6/8
(75%) of persons who developed neurodegenerative disease had
abnormal imaging 2.5 years before diagnosis, compared to 31% of
those who were still disease free.28 Transcranial ultrasound was normal
at baseline in 5/8 (62.5%), compared to 29% of those who were still
disease free.28 Finally, patients with RBD who eventually developed
disease showed evidence of hippocampal hyperperfusion on whole-
brain glucose utilization SPECT (a common finding in early
dementia), compared to those who did not develop disease (Thanh,
in press).
Therefore, studies in patients with RBD have already provided
direct evidence that dopaminergic imaging, olfaction, color loss, and
whole-brain glucose utilization can identify prodromal neurodegen-
erative disease. As research continues, this list of proven markers will
likely continue to expand.
Watching PD develop
The above studies included mainly patients with idiopathic RBD
and compared those who developed disease to those remained disease
free. Although this approach allows one to ‘prove’ that a given marker
predicts PD, there are limitations. First, the comparison group (disease-
free RBD) can be problematic – as the longest duration studies are
being reported, it is clear that the risk of developing synucleinopathy
approaches 65–80%29. Therefore, the large majority of patients with
‘idiopathic’ RBD may in fact have prodromal disease. In long-term
cohort studies, it becomes increasingly difficult to find a ‘disease-free’
comparison group, and even when these are defined, it may really be a
matter of disease stage rather than disease state. This implies that it may
be most informative to compare baseline findings in RBD patients who
eventually developed disease to age-matched controls. Another
limitation is that RBD is predominantly related to pontomedullary
dysfunction and is therefore likely a marker of Braak Stage II.30 This
could imply that many Stage I markers (e.g., autonomic dysfunction,
olfaction) may already be at ‘floor’ levels by the time a patient presents
with RBD. If this is the case, many still-idiopathic patients would
already be maximally abnormal on the marker, resulting in false
negative results when ‘disease vs. disease-free’ comparisons are used.
Finally, although it is useful to provide evidence that a marker can
predict disease, there are many other important questions to answer,
such as how do markers evolve in prodromal disease, when do they
become abnormal, and when can a patient in prodromal PD stages be
identified?
Some recent studies are tackling these more complex questions by
measuring change in prodromal disease markers over prospective
periods. A recent study compared the evolution of motor changes in
patients with idiopathic RBD who had developed parkinsonism to
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age-matched controls.18 This analysis estimated that prodromal
parkinsonism first becomes detectible approximately 4.5 years before
overt disease onset. Hypomimia and hypophonia may begin first,
followed by limb bradykinesia, rigidity, and finally tremor. Using a
cutoff on the Unified Parkinson Disease Rating Scale Part III of .3
points (excluding action tremor), prodromal parkinsonism could be
identified 2 years before clinical disease diagnosis with a sensitivity of
94% and a specificity of 97% (longer prodromal intervals had much
lower sensitivity). Perhaps of even more significance for future
screening programs, simple non-expert quantitative motor testing
demonstrated abnormalities approximately 6–9 years before diagnosis
of parkinsonism and could identify parkinsonism with approximately
80% sensitivity and specificity up to 3 years before disease diagnosis.
Simply comparing ‘disease-free RBD’ to ‘idiopathic RBD-then disease’
would have only answered the relatively trivial question of whether
motor findings are present before PD diagnosis; however, assessing
progression at annual follow-up allowed a direct examination of
prodromal disease evolution. Similarly, a study assessing dopaminergic
functional imaging found that patients with RBD had more rapid
decline than age-matched controls (15–19% vs. 10%).28 This suggests
that dopaminergic function progressively declines in RBD (as
expected) but also provides baseline and expected progression values
that can be used if dopaminergic imaging becomes a surrogate marker
in neuroprotective trials. Prospective studies of olfaction and color
vision have also demonstrated relatively slow progression in at least the
last 4 years of prodromal disease, suggesting that these functions may
become abnormal many years before full clinical disease develops.21
Another angle afforded by thinking of RBD patients as prodromal
PD patients rather than ‘at-risk’ patients comes from recent studies
performed by members of the RBD study group. A large case-control
study (347 patients, 347 controls) found that similar to PD and
dementia, pesticide use, head injury, farming, and low years of
education were risk factors for RBD31. However, the differences
between RBD and PD were of special interest. Every large
epidemiologic study has found that caffeine non-use and non-smoking
are risk factors for PD. However, caffeine was not associated with
RBD, and smoking was associated with higher risk. This raises the
intriguing possibility that caffeine and nicotine ‘prevent’ PD by
specifically targeting basal ganglia motor structures rather than
preventing synucleinopathy in general. That is, synucleinopathy
proceeds unimpeded, but clinical expression in motor structures is
prevented or delayed. Analyses of family history, co-morbidities,
medications, and autonomic dysfunction are underway in this cohort.
Prospective follow-up studies will allow the assessment of environ-
mental risk factors as predictors of disease outcome – for example,
could smoking and caffeine non-use indicate a higher risk of dementia
rather than primary motor parkinsonism?
Neuroprotection
One of the most important factors hampering neuroprotective
therapy development for neurodegenerative disease is that the disease
process is well established by the time a patient presents to their
physician with clinical symptoms. This severely limits the ability to
intervene in early stages, when protective treatments might be most
effective. In this regard, RBD patients provide an important
opportunity – they are the ideal group to include in clinical trials of
neuroprotective therapies for ‘preventing’ synuclein-mediated neuro-
degeneration. RBD patients have two essential characteristics required
for such a trial. First, they have a very high ‘risk’ of disease conversion,
and second, the latency is long enough that the intervention can be
provided early enough to affect change.
Can a neuroprotective trial for RBD be developed? Such a trial
would have numerous challenges to overcome. First, the long latency
to development of defined disease, although a major advantage in
terms of opportunity to intervene early, does imply that trials would
need to be of sufficiently long duration. It is unlikely that a
pharmaceutical company with a patent-protected product would be
interested in funding such long-term trials because the patent would
expire soon after publication. Selecting patients who already have
ancillary evidence of neurodegeneration, such as dopaminergic
denervation on SPECT or olfactory loss, may mitigate this (although
at the cost of intervening later in the disease process). For example,
addition of olfaction as a selection criterion would produce up to a
65% ‘conversion’ rate in a 5-year trial, and if even this is not
sufficiently high to plan adequately powered trials of reasonable size,
further stratification with dopaminergic imaging would likely produce
even higher conversion rates. Second, just like in established disease,
symptomatic confounds may also confound outcome interpretation if
the definition of the endpoint (i.e., disease diagnosis) is altered by
symptomatic motor or cognitive effects. For example, if development
of defined parkinsonism on examination is an outcome of the trial, and
patients are given an agent that improves parkinsonism symptoms, the
diagnosis would be delayed, resulting in an apparent ‘protective’ effect.
Third, given that RBD patients develop both motor impairment and
dementia, agents that target synucleinopathy in general rather than
just the substantia nigra are more likely to be useful. Regardless of
these challenges, there is probably no other clinical group that can
provide the combination of specificity for prodromal PD and adequate
lead time that is so essential to a successful neuroprotective trial.
Finally, any consideration of future research points us towards the
most important direction that RBD research must take, that is, to
collaborate. Because RBD patients rarely present in large numbers to
any single center, the most essential future studies, including trials of
symptomatic therapy, neuroprotective studies, and large-scale evalua-
tions of prodromal disease, can only be answered through open and
intensive collaborations among centers. As our networks of collabora-
tion improve, opportunity for real advance continues to expand.
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